Quetiapine Fumarate XR Tablets
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D223D0012
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
This procurement notice announces the award modification for contract SPE2D223D0012, specifically Modification P00009, which exercises Option Year 3 for the supply of Quetiapine Fumarate XR Tablets. The contract is managed by DLA Troop Support, a federal office under the Defense Logistics Agency (DLA), which operates within the Department of Defense. The primary objective of this procurement is to ensure the continued, reliable supply of Quetiapine Fumarate XR Tablets, a pharmaceutical product classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505 (Drugs and Biologicals).
The place of performance for this contract is Hauppauge, New York, indicating that manufacturing, distribution, or fulfillment activities related to this requirement will be centered in this location. The ongoing nature of this contract, as evidenced by the exercise of an option year, underscores the DLA’s commitment to maintaining a consistent supply chain for critical pharmaceutical products used in support of military and federal healthcare operations.
Key requirements for this contract include the manufacturing and timely delivery of Quetiapine Fumarate XR Tablets in accordance with federal standards and specifications. Contractors are expected to adhere to stringent quality assurance protocols and regulatory compliance as dictated by the Department of Defense and relevant federal agencies. The scope of work encompasses all activities necessary to ensure the availability of these extended-release tablets for end users within the federal system.
The procurement is classified as an award notice, indicating that the contract has already been awarded and is currently active. The modification to exercise Option Year 3 reflects the government’s satisfaction with the contractor’s performance and the ongoing need for these pharmaceutical supplies. While the notice does not specify set-aside requirements or special considerations, contractors should note that the opportunity is managed by a federal entity with established procurement protocols.
For further information or contract administration matters, the primary point of contact is Nancy Fernandez ([email protected], 215-737-4955), with Jason Wray ([email protected], 215-737-0614) serving as the secondary contact. Additional details and attachments related to this notice can be accessed via the official SAM.gov opportunity page.
In summary, this contract modification ensures the uninterrupted provision of Quetiapine Fumarate XR Tablets to meet the ongoing needs of the Department of Defense, with performance centered in Hauppauge, NY, and oversight provided by DLA Troop Support. Contractors with capabilities in pharmaceutical preparation manufacturing and experience in federal supply contracts may find this opportunity aligns with their expertise, particularly in supporting long-term government healthcare requirements.
Documents6